Literature DB >> 11205281

Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma.

A Ghellal1, C Li, M Hayes, G Byrne, N Bundred, S Kumar.   

Abstract

Transforming growth factor beta s (TGF beta s) are multifunctional growth factors which show differential expression both temporally and spatially and exert pleiotropic effects during carcinogenesis. Although all three mammalian isoforms of TGF beta share considerable sequence similarity, they appear to have distinct functions in health and disease, such as embryogenesis, wound healing and tumourigenesis. Much of our knowledge about the relationship between TGF beta s and breast cancer is based on publications on TGF beta 1 but the role of TGF beta 3 in the progression of breast cancer has not been well documented. In the present study, the expression of TGF beta 1 and TGF beta 3 was assessed by immunohistochemistry. Of the 153 invasive breast cancer tissues, TGF beta 1 was expressed strongly in 25 and moderately in 98 cases. The immunoreactivity of TGF beta 3 was comparable with TGF beta 1, which was expressed strongly in 21 and moderately in 104 cases. The two isoforms were coexpressed in 111 (72.5%) tumours and were absent in 16 cases (10%). Immunostaining for TGFb3 but not TGF beta 1 was inversely correlated with overall survival (p = 0.0204). When combined with lymph node involvement, TGFb3 became an even more significant prognostic factor for overall survival (p = 0.0003), i.e. patients with node metastasis and positive TGFb3 expression had a worse prognosis: the risk of death for these patients was thirteen-fold greater than those who had no node involvement. The fact that it has been reported previously that high TGF beta 3 plasma levels in patients with untreated early stage breast cancer were correlated with subsequent lymph node metastasis and it was observed in the present study too, that TGF beta 3 expression in breast tumours was an independent predictor of overall survival, led us to suggest that the simultaneous measurement of TGF beta 3 in plasma and its expression in resected tumour tissues in the same cohort of patients may prove to be an important parameter in assessing tumour progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205281

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  29 in total

1.  Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Masatomo Miura; Yudai Hinai; Hajime Saito; Manabu Ito; Takashi Ono; Hiroshi Toda; Satoru Motoyama; Jun-ichi Ogawa
Journal:  Tumour Biol       Date:  2010-05-27

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  Spheroid assay to measure TGF-β-induced invasion.

Authors:  Hildegonda P H Naber; Eliza Wiercinska; Peter Ten Dijke; Theo van Laar
Journal:  J Vis Exp       Date:  2011-11-16       Impact factor: 1.355

4.  Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.

Authors:  Judy C Pang; Nilam K Virani; Kelley M Kidwell; Celina G Kleer
Journal:  J Cell Commun Signal       Date:  2014-08-19       Impact factor: 5.782

5.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

Review 6.  Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.

Authors:  Douglas S Micalizzi; Susan M Farabaugh; Heide L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-19       Impact factor: 2.673

7.  Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics.

Authors:  Jonine D Figueroa; Kathleen C Flanders; Montserrat Garcia-Closas; William F Anderson; Xiaohong R Yang; Rayna K Matsuno; Máire A Duggan; Ruth M Pfeiffer; Akira Ooshima; Robert Cornelison; Gretchen L Gierach; Louise A Brinton; Jolanta Lissowska; Beata Peplonska; Lalage M Wakefield; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2009-11-24       Impact factor: 4.872

8.  Stage-related plasma values of transforming growth factor-beta1 are steroid receptors dependent.

Authors:  Natasa Todorović-Raković; Z Nesković-Konstantinović; D Nikolić-Vukosavljević
Journal:  Clin Exp Med       Date:  2009-05-21       Impact factor: 3.984

Review 9.  TGF-beta3 and cancer: a review.

Authors:  H G Laverty; L M Wakefield; N L Occleston; S O'Kane; M W J Ferguson
Journal:  Cytokine Growth Factor Rev       Date:  2009-08-04       Impact factor: 7.638

10.  Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.

Authors:  C Li; R Gardy; B K Seon; S E Duff; S Abdalla; A Renehan; S T O'Dwyer; N Haboubi; S Kumar
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.